10-Q · May 12, 2026
The extracted 10-Q text does not include income-statement, segment, balance-sheet, or cash-flow data, so revenue, margins, EPS, and free cash flow cannot be assessed. Liquidity was supported by the November 2025…
Earnings analysis · 10-Q
Filed August 13, 2026 · Our reading of the company's report
The latest report
The filing does not provide income-statement, segment, balance-sheet or cash-flow figures in the extracted text, so revenue, margins, EPS and free cash flow cannot be assessed. The dominant developments are severe…
The filing does not provide income-statement, segment, balance-sheet or cash-flow figures in the extracted text, so revenue, margins, EPS and free cash flow cannot be assessed. The dominant developments are severe listing and financing risks: Nasdaq denied continued listing after citing the $2.5 million equity requirement, although trading remains stayed pending an August 25, 2026 hearing. The company also reported ineffective disclosure controls due to two material weaknesses, while stating that a significant portion of its $3,235,692 net offering proceeds remained available for operations.
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
The company timely requested a Nasdaq hearing, which stayed suspension of trading and the filing of Form 25-NSE pending the Panel’s decision. The hearing is scheduled for August 25, 2026.
The November 2025 public offering generated $4,000,000 of gross proceeds and $3,235,692 of net proceeds after $764,308 of discounts, commissions and expenses.
Management stated that a significant portion of the $3,235,692 net offering proceeds remained unutilized and was held as cash and cash equivalents as of June 30, 2026.
The company is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires at least $2.5 million of stockholders’ equity. Nasdaq denied continued-listing relief on July 15, 2026 because the company lacked a definitive financing agreement.
If the Nasdaq appeal is unsuccessful, the company’s common stock could be suspended and delisted, reducing liquidity and impairing its ability to raise capital. The Nasdaq Panel hearing is scheduled for August 25, 2026, and any exception may be subject to milestones.
A newly approved Nasdaq rule would require at least $5 million of market value of listed securities and could trigger immediate suspension and delisting after 30 consecutive business days below the threshold. The rule’s approval order was stayed on July 29, 2026 and is not currently effective.
Disclosure controls and procedures were ineffective as of June 30, 2026 because the internal-control system failed to identify multiple auditor-identified journal entries and lacked a formal related-party transaction approval process.
No quantitative revenue or EPS outlook was provided in the extracted 10-Q. The report states that remaining offering proceeds will support ongoing operations, product development and potential strategic initiatives.
The extracted 10-Q text does not include income-statement, segment, balance-sheet, or cash-flow data, so revenue, margins, EPS, and free cash flow cannot be assessed. Liquidity was supported by the November 2025…
Caring Brands remains an extremely early-stage wellness-products company: 2025 revenue was only $4,215 against a $6,278,191 net loss, negative $1,692,258 operating cash flow, and a $5,935,025 operating loss. The IPO…
The provided filing excerpt does not include the financial statements, income statement trends, segment results, balance sheet, or cash-flow data, so operating performance cannot be assessed. The principal disclosed…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.